Skip to main content
Main navigation
Schizophrenia Foundations
Symptomatology
Patient Burden
Caregiver Perspectives
Psychopharmacology
Search
Main navigation
Schizophrenia Foundations
Symptomatology
Patient Burden
Caregiver Perspectives
Psychopharmacology
Search
Psychopharmacology
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?
Welcome to Schizophrenia Knowledge Base
This website is intended for healthcare professionals in the United States.
Yes, I am a US healthcare professional
No, I am not a US healthcare professional
CME: Harnessing the Evolving Understanding of Schizophrenia to Address Treatment Challenges and Unmet Needs
Understanding the Cholinergic System
Assessing Anticholinergic Burden
Anticholinergic Misuse: Can These Medications Be Addictive?
Can Anticholinergic Medications Make Movement Disorders Worse?
What’s the Role of Amantadine in Anticholinergic Deprescription?
CME: The Future of Schizophrenia Care: A Closer Look at the Role of Muscarinic Acetylcholine Receptor Activation
CME: Emerging Therapeutic Targets for Schizophrenia: A Focus on Muscarinic Acetylcholine Receptor Activation
Navigating the A to Z of Schizophrenia, Part 3: Novel Treatment Mechanisms
CME: Great Debates: Exploring Muscarinic Agonists in Schizophrenia Treatment
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Current page
2
Page
3
Page
4
Page
5
Next page
Next ›
Last page
Last »